T-cell Lymphoma

T-cell lymphomas are a heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature T cells and NK cells. Subtypes include peripheral T-cell lymphoma NOS (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL/Mycosis Fungoides), extranodal NK/T-cell lymphoma (ENKTL), adult T-cell leukemia/lymphoma (ATLL), and others. Brentuximab vedotin plus CHP is the frontline standard for CD30+ PTCL; mogamulizumab and HDAC inhibitors are key options in relapsed disease.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for T-cell Lymphoma

• Brentuximab Vedotin (Adcetris) — Antibody-Drug Conjugate
• Mogamulizumab (Poteligeo) — Monoclonal Antibody
• Romidepsin (Istodax) — Other
• Pralatrexate (Folotyn) — Antimetabolite
• Belinostat (Beleodaq) — Other
• Vorinostat (Zolinza) — Other
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Methotrexate (Trexall) — Antimetabolite
• Doxorubicin (Adriamycin) — Anthracycline
• Etoposide (VePesid) — Topoisomerase Inhibitor
• Cyclophosphamide (Cytoxan) — Alkylating Agent
• Vinblastine (Velban) — Vinca Alkaloid
• Bendamustine (Treanda) — Alkylating Agent
• Gemcitabine (Gemzar) — Antimetabolite